COLLEGE of AMERICAN PATHOLOGISTS

CAP Laboratory COVID-19 Impact Study
June 2020

Survey Objective and Methodology

Objectives

- To determine how the COVID-19 pandemic is impacting CAP accredited laboratories in the United States so CAP can better inform leaders, elected officials, and government regulators of the challenges laboratories are facing.
- To identify what laboratories need as they strive to deliver quality testing for the patient populations they serve.

Methodology

- Target Audience: CAP Accredited Laboratories in the US
- Respondent Profile: Laboratory Directors in the US
- Study Format: Online study (3,723 invitations). Initial invitation sent on June 8, 2020 and study closed on June 13, 2020.

Questions/Responses Reported

Which of the following best describes your laboratory's COVID-19 testing status?

	Currently Performing On-Site	Plan to Perform On-Site Within the Next 2 Weeks	Plan to Perform On-Site Within the Next 4 Weeks	Do not Plan on Performing On-Site	n
High throughput testing (i.e., a platform that employs automated processing of more than 200 specimens a day)	35%	4%	12%	48%	306
Non-high throughput testing (which includes the CDC test, some rapid testing and some LDTs)	65%	3%	7%	25%	306

	June	**April**
Testing	76%	59%
Planning on Testing	9%	9%
Not Testing	15%	32%
n	306	434

*"Testing": Respondent indicated testing either high-throughput testing, non-high throughput testing, or both.

Using your best estimate…

a) What was the average daily COVID-19 test volume for the past 7 days?

b) What is your <u>daily</u> COVID-19 testing capacity? (ie, the average daily number of COVID-19 tests for which your laboratory has adequate supplies and staff to test)?

c) What is your laboratory's daily instrument testing capacity for COVID-19? (ie, number of COVID-19 tests your testing platform(s) is able to run per day)

	%	n
Testing capacity exceeds testing volume	70%	119
Testing at capacity	15%	26
Testing volume exceeds testing capacity	14%	25

On how many unique platforms does your laboratory perform COVID-19 molecular testing? (n= 203)

1	40%
2	33%
3	10%
4	10%
5	6%
6	2%
7	1%

How difficult has it been for your laboratory to acquire each of the following specific items for COVID-19 testing? (5 = Very difficult, 1=Not at all difficult)

	5/4	**3**	**2/1**	**n**
Reagents for platforms/test kits	64%	20%	16%	208
Flocked nasopharyngeal swabs to collect and transport patient samples	60%	25%	15%	212
Viral transport media/universal transport media (VTM/UTM)	55%	25%	19%	213
SARS-COV-2 instruments	43%	19%	38%	196
Extraction platform	42%	22%	37%	143
Extraction control material	34%	24%	42%	150
Personal protective equipment (PPE)	30%	30%	40%	222
Assay positive control material	25%	28%	47%	197

Which of these have occurred in your laboratory for each of the following roles as a result of COVID-19? (select all that apply)

	Pathologists	Non-pathologist
Reduced work hours	63%	63%
Reductions in pay	43%	18%
Hiring freezes	42%	56%
Increased burnout	36%	46%
Increased work hours	28%	29%
Rescinded vacation days	25%	20%
Reductions in employer-provided benefits	21%	14%
Temporary furloughs	16%	41%
Reduced staff capacity (staff shortages, staff self-quarantining, etc.)	12%	49%
Increased personnel costs (overtime, temporary staff, etc.)	0%	35%
Permanent layoffs	0%	9%
n	214	240

Using your best estimate, how has the volume of non-COVID-19 clinical pathology and anatomic pathology testing changed compared to the same period in 2019?

	JUNE		**APRIL**	
	Median	**Average**	**Median**	**Average**
Non-COVID-19 Clinical Pathology (% change)	-38%	-34%	-46%	-41%
Anatomic Pathology (% change)	-50%	-48%	-69%	-64%